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ABSTRACT: The World Health Organization (WHO) European region estimates that more than
400,000 tuberculosis (TB) cases occur in Europe, a large proportion of them among migrants.
A coordinated public health mechanism to guarantee TB prevention, diagnosis, treatment and
care across borders is not in place. A consensus paper describing the minimum package of
cross-border TB control and care was prepared by a task force following a literature review, and
with input from the national TB control programme managers of the WHO European region and
the Wolfheze 2011 conference. A literature review focused on the subject of TB in migrants was
carried out, selecting documents published during the 11-yr period 2001–2011.
Several issues were identified in cross-border TB control and care, varying from the limited
access to early TB diagnosis, to the lack of continuity of care and information during migration,
and the availability of, and access to, health services in the new country.
The recommended minimum package addresses the current shortcomings and intends to
improve the situation by covering several areas: political commitment (including the implementa-
tion of a legal framework for TB cross-border collaboration), financial mechanisms and adequate
health service delivery (prevention, infection control, contact management, diagnosis and
treatment, and psychosocial support).
KEYWORDS: Control, Europe, human rights, immigration, multidrug-resistant tuberculosis,
tuberculosis
T
uberculosis (TB), HIV/AIDS and malaria are
important clinical and public health issues
worldwide. The World Health Organization
(WHO) estimates that 8.8 million new TB cases and
1.4 million deaths occurred in 198 countries due to
TB in 2010 [1]. Of these numbers, 418,000 patients
and 60,000 deaths due to TB are estimated in the
WHO European region, a large proportion of them
among migrants [2]. Despite the wide difference in
TB notification in the region (from 2.8 to 123 per
100,000 population), TB is considered a public
health problem in most countries, particularly
among the vulnerable populations (i.e. individuals
at higher risk of exposure to discrimination,
hostility or economic adversity) frequently located
in cities of low incidence countries [3, 4]. The
reported treatment success of patients in the WHO
European region have been, aberrantly, the lowest
among all WHO regions, with 68.7% and 47.6% for
the 2009 cohorts of new and previously treated
patients, respectively. During the same period,
default rates were up to 6.4% and 11.3% among
new and previously treated patients, respectively.
Most patients moving from one country to another
are lost to follow-up (defaulters, transfers out and
unknown) with 11%, 17% and 22% among new,
previously treated and multidrug-resistant (MDR)-
TB patients, respectively [1, 2].
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Several factors have led to an increase of population mobility in
the WHO European region, including establishment of the
European Union (EU) and free movement within the Newly
Independent States, particularly for seasonal labour. The
increased population mobility requires an effective and sustain-
able mechanism to coordinate interventions ensuring quality TB
prevention and care, including early diagnosis, uninterrupted
treatment and patient support across borders (fig. 1) [6].
Quality diagnosis and treatment of TB are both individual
human rights (independent of legal or residential status of the
patient) and public health pre-requisites to prevent further
development of MDR-TB and extensively drug-resistant
(XDR)-TB. Given the alarming increase in prevalence of drug
resistance in the WHO European region, a specific regional
effort was conducted [7] to complement the global efforts to
eliminating TB by 2050, as targeted by the Stop TB Partnership
(table 1) [8].
The rights to health and access to healthcare are defined in
article 12 of the 1966 United Nations International Covenant on
Economic, Social and Cultural Rights and ratified by most of
the countries in the world [9]. For health authorities, there is an
internationally agreed ethical obligation to provide universal
access to TB and drug-resistant TB care, which should include
the use of quality drugs free of charge for all patients through
culturally competent and gender sensitive services [10]. These
services have to be tailored for those individuals who face
increased risk of getting infected with TB and developing
active TB, and for those with higher risk of defaulting
treatment and having challenges of accessing and fully
utilising services, including refugees, asylum seekers, migrants
and mobile populations [11]. For undocumented migrants, the
International Union against Tuberculosis and Lung Disease
specifically recommends that easy access to TB diagnosis is
ensured and that no deportation takes place until the end of




FIGURE 1. Net migration rate in Europe (difference between the number of persons entering and leaving a country during the year per 1,000 persons). Adapted from [5].
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TABLE 1 Tuberculosis reported new cases by geographic origin in the World Health Organization European region, 2010
Country Criteria for origin Native Foreign Unknown Total
EU/EEA
Austria Citizenship 385 (56.0) 299 (43.5) 4 (0.6) 688
Belgium Citizenship 506 (45.4) 609 (54.6) 0 (0.0) 1115
Bulgaria Birthplace 2647 (99.9) 2 (0.1) 0 (0.0) 2649
Cyprus Birthplace 11 (18.0) 50 (82.0) 0 (0.0) 61
Czech Republic Birthplace 561 (82.7) 117 (17.3) 0 (0.0) 678
Denmark Birthplace 143 (39.8) 216 (60.2) 0 (0.0) 359
Estonia Birthplace 271 (82.4) 58 (17.6) 0 (0.0) 329
Finland Birthplace 217 (66.4) 105 (32.1) 5 (1.5) 327
France Birthplace 2264 (44.3) 2469 (48.3) 383 (7.5) 5116
Germany Birthplace 2213 (51.1) 1978 (45.7) 139 (3.2) 4330
Greece Birthplace 258 (52.8) 231 (47.2) 0 (0.0) 489
Hungary Citizenship 1720 (98.8) 21 (1.2) 0 (0.0) 1741
Iceland Birthplace 6 (27.3) 16 (72.7) 0 (0.0) 22
Ireland Birthplace 243 (56.9) 171 (40.0) 13 (3.0) 427
Italy Birthplace 1418 (43.6) 1809 (55.7) 22 (0.7) 3249
Latvia Birthplace 872 (93.4) 62 (6.6) 0 (0.0) 934
Lithuania Birthplace 1891 (97.6) 47 (2.4) 0 (0.0) 1938
Luxembourg Birthplace 12 (41.4) 17 (58.6) 0 (0.0) 29
Malta Birthplace 7 (21.9) 25 (78.1) 0 (0.0) 32
The Netherlands Birthplace 275 (25.6) 789 (73.5) 9 (0.8) 1073
Norway Birthplace 50 (14.7) 289 (85.3) 0 (0.0) 339
Poland Citizenship 7463 (99.4) 46 (0.6) 0 (0.0) 7509
Portugal Birthplace 2197 (83.7) 425 (16.2) 4 (0.2) 2626
Romania Birthplace 21040 (99.8) 38 (0.2) 0 (0.0) 21078
Slovakia Birthplace 431 (98.2) 8 (1.8) 0 (0.0) 439
Slovenia Birthplace 131 (76.2) 41 (23.8) 0 (0.0) 172
Spain Birthplace 4652 (65.6) 2268 (32.0) 169 (2.4) 7089
Sweden Birthplace 96 (14.2) 579 (85.8) 0 (0.0) 675
UK Birthplace 2131 (25.1) 5816 (68.6) 536 (6.3) 8483
Subtotal EU/EEA 54111 (73.1) 18601 (25.1) 1284 (1.7) 73996
Non-EU/EEA
Albania Citizenship 444 (99.8) 1 (0.2) 0 (0.0) 445
Andorra Citizenship 7 (100.0) 0 (0.0) 0 (0.0) 7
Armenia Citizenship 1779 (99.9) 1 (0.1) 0 (0.0) 1780
Azerbaijan Citizenship 8394 (100.0) 8394
Belarus Citizenship 5153 (92.8) 0 (0.0) 401 (7.2) 5554
Bosnia and Herzegovina Citizenship 1390 (100.0) 0 (0.0) 0 (0.0) 1390
Croatia Birthplace 691 (99.4) 4 (0.6) 0 (0.0) 695
Georgia Citizenship 5796 (100.0) 0 (0.0) 0 (0.0) 5796
Israel Birthplace 51 (14.9) 292 (85.1) 0 (0.0) 343
Kazakhstan Birthplace 24847 (87.0) 0 (0.0) 3703 (13.0) 28550
Kyrgyzstan Birthplace 5308 (84.3) 0 (0.0) 987 (15.7) 6295
Macedonia, the former Yugoslav Republic of Birthplace 0 (0.0) 0 (0.0) 420 (100.0) 420
Moldova Citizenship 5416 (99.4) 31 (0.6) 0 (0.0) 5447
Monaco Birthplace 0 (0.0) 1 (100.0) 0 (0.0) 1
Montenegro Citizenship 113 (99.1) 1 (0.9) 0 (0.0) 114
Russia Citizenship 107794 (66.3) 2110 (1.3) 52649 (32.4) 162553
San Marino
Serbia 2385 (100.0) 2385
Serbia, excluding UN-administered province of
Kosovo
Citizenship 1501 (100.0) 1501
UN-administered province of Kosovo Birthplace 884 (100.0) 0 (0.0) 0 (0.0) 884
Switzerland Birthplace 150 (27.3) 377 (68.7) 22 (4) 549
Tajikistan Birthplace 7641 (100.0) 7641
Turkey Birthplace 16551 (100.0) 16551
Turkmenistan Citizenship 3230 (100.0) 3230
Ukraine Citizenship 36409 (100.0) 36409
Uzbekistan Birthplace 20330 (100.0) 20330
Subtotal Non-EU/EEA 158789 (50.4) 2441 (0.8) 153649 (48,8) 314879
Total 212900 (54.7) 21042 (5.4) 154933 (39.8) 388875
Subtotal 18 HPC 182814 (54.2) 2349 (0.7) 150295 (44.8) 335458
Data are presented as n or n (%). EU: European Union; EEA: European Economic Area; UN: United Nations; HPC: high priority countries.
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TB suspects is enforced and if vulnerable individuals, such as
asylum seekers or undocumented migrants, are diagnosed
with TB, they may be extradited without continuity of TB
treatment being ensured [12–15]. For TB patients crossing
national borders, there is often lack of continuity of treatment
due to lack of patient-centred approaches and/or availability
of sound transfer mechanisms [13–15].
Under the Wolfheze’s movement initiative, a task force [16] of
experts discussed the minimum package of cross-border TB
control and care [17]. A literature review was conducted and
the concept paper was discussed and finalised with input from
the national TB control programme managers of the WHO
European region and Wolfheze 2011. This consensus paper
defines the minimum package of cross-border TB control and
care in the WHO European region.
METHODS
A review of the evidence relevant for the development of this
document was performed. PubMed, EMBASE results and grey
literature were evaluated in order to find articles dealing with
the topic "TB and migration"; the selected publication period
was January 2001 to December 2011. In addition, all the
abstracts published over the same period in the International
Journal of Tuberculosis and Lung Disease were checked.
Combinations of the following search terms were used:
‘‘tuberculosis’’, ‘‘multidrug-resistant tuberculosis’’, ‘‘exten-
sively drug-resistant tuberculosis’’, ‘‘MDR’’, ‘‘XDR’’, ‘‘immigra-
tion’’, ‘‘migration’’, ‘‘migrants’’, ‘‘human rights’’, ‘‘asylum
seekers’’, ‘‘ethnic minorities’’ and ‘‘Europe’’. The search was
not restricted to publications in English. In addition, biblio-
graphies of retrieved articles were also hand-searched and
relevant documents were provided by the national delegates
represented in Wolfheze workshops.
Citations were independently screened by three investigators
(M. Dara, A. Sandgren and G.B. Migliori) by examining titles
and abstracts to identify potentially relevant studies, and
differences were resolved by consensus.
The evidence collected was organised in the following sections:
key challenges, relevant legal framework, international health
regulations and European experiences. On the basis of this
evidence, the minimum package for cross-border TB control
and care was finally developed by the task force.
DEFINITIONS
A ‘‘migrant’’ is an individual who changes his/her nation of
usual residence [3].
A ‘‘long-term migrant’’ is defined as a subject who moves to a
nation other than that of his/her usual residence for
o365 days (the country of destination becomes his/her new
country of residence) [3].
A ‘‘short-term migrant’’ is defined as a subject moving to
a country other than that of his/her usual residence for a
period ranging from o3 months to ,12 months, except for
holiday, visits to friends and relatives, business, medical
assistance or pilgrimage [3].
An ‘‘undocumented migrant’’ is a person who, owing to
unauthorised entry or the expiry of his/her visa, lacks legal
status in a transit or host country. ‘‘Illegal’’ is not used because
it implies a criminal connotation [3].
According to the 1951 Refugee Convention, a ‘‘refugee’’ is some-
one who, owing to a well-founded fear of being persecuted
because of race, religion, nationality, politics or membership of a
particular social group, is outside his/her usual country of
residence, and is unable to, or unwilling to, avail himself/herself
of the protection of that country [3].
An ‘‘asylum seeker’’ is a person seeking security from per-
secution in a country other than his/her own and awaits a
decision on the application for refugee status under relevant
international and national instruments. In case of a negative
decision, he/she may be expelled unless permission to stay is
provided on humanitarian or other related grounds.
A ‘‘migrant worker’’ is a person who is to be engaged, is
engaged or has been engaged in a remunerated activity in a state
of which he or she is not a national (article 2(1), International
Convention on the Protection of the Rights of All Migrant Workers
and Members of Their Families, 1990) [3].
‘‘MDR-TB’’: TB caused by mycobacterial strains showing in
vitro resistance to at least isoniazid and rifampicin, the two
most potent first-line drugs for TB treatment [1].
‘‘XDR-TB’’: TB caused by mycobacterial strains showing in
vitro resistance to isoniazid and rifampicin plus any fluor-
oquinolone and at least one of the injectable second-line drugs;
amikacin, capreomycin or kanamycin [1].
‘‘Europe’’ is defined as the WHO European region, composed
of 53 member states, if not otherwise specified [17].
‘‘EU’’ indicates the European Union, composed of 27 member
states [18].
‘‘EEA’’ refers to the European Economic Area.
‘‘Individuals crossing borders’’: for practical purposes, the
current paper refers to all individuals who, for any reason,
travel from one country to another for any period of time [3].
‘‘Wolfheze’’: a series of workshops named after a village in the
Netherlands where KNCV Tuberculosis Foundation, WHO and
other technical agencies jointly organised a series of workshops,
known as the ‘‘Wolfheze Workshops’’, for the National TB
Programme (NTP) managers of low TB prevalence countries in
western Europe. The aim of the workshops was to redefine TB
control in the WHO European region, with emphasis on
formulating guidelines and standards based on a consensus-
building approach. Consensus was attained through extensive
consultations among TB control experts, national correspon-
dents and representatives of health ministries. This group was
later expanded to all countries of the region.
KEY CHALLENGES OF CROSS-BORDER TB CONTROL
AND CARE
Countries of the WHO European region face an array of
challenges in cross-border TB control. These include limited
access to early TB diagnosis, a lack of continuity of care for TB
patients when they move to another country, and no or little
information to the health providers in the countries of transit,
destination and return [17–19]. In addition, there is often lack of
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appropriate and/or adequate information for patients as to their
rights, availability of health services, coverage entitlements and
accessibility of services [12, 18, 20]. In some countries, there is no
provision for the coverage of the costs of TB diagnosis and
treatment, which mainly rely on individual payment. Accessing
healthcare can be a special challenge for migrants [17, 20]. These
are further complicated by cultural and language barriers,
stigma and fear of deportation.
The fear of discrimination and, furthermore, of deportation
because of TB may result in the hiding symptoms and delay in
diagnosis, commencement of self-treatment or even a treatment
already started to be discontinued, which can eventually lead
to development of (multi)drug-resistant TB [12]. Deporting
migrants can cause the discontinuation of their treatment [19],
even when deported to other EU countries of the Schengen area
[note: the Schengen Area currently consists of 26 states (Austria,
Belgium, Czech Republic, Denmark, Estonia, Finland, France,
Germany, Greece, Hungary, Iceland, Italy, Latvia, Liechtenstein,
Lithuania, Luxembourg, Malta, the Netherlands, Norway,
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and
Switzerland), all but four of which are members of the EU
(Iceland, Norway, Switzerland and Liechtenstein)].
The shortcomings of TB care across borders stem from lack
of coordination between the member states of the WHO
European region, inadequate legal framework and insufficien-
cies of health systems to deal with cross-border TB control and
care, including accurate and adequate data collection [18–20].
For example, geographic origin of patients is reported in 98.3%
of cases in EU/EEA countries, but in only 51.2% of cases in
non-EU/EEA countries [2].
RELEVANT LEGAL AND POLICY FRAMEWORK FOR
CROSS-BORDER TB CONTROL AND CARE
The legal framework applied in the WHO European region for
cross-border TB control and care is quite different among
countries. While in some countries free TB diagnosis and
treatment is provided to all residents irrespective of their
nationality or status (e.g. Norway and Kazakhstan), in others a
legal framework allowing free access to health services does not
exist, is not fully developed, or is not applied in practice. In some
countries, health professionals and social workers are prevented
by law from reporting TB cases to police/immigration autho-
rities, while in others health professionals and social workers are
required to do so, regardless of their professional oath.
In the EU countries, the European Council Regulation 343 of
February 2003, known as ‘‘Dublin II Regulation’’ [21], has
established the criteria and mechanisms for determining the
country responsible for examining asylum applications by a
third-country national. This regulation was issued to limit the
‘‘asylum shopping’’ and to ensure that each asylum applicant’s
case is processed by one country only. It is usually the country
where the application was deposited first that has the
responsibility of providing asylum (even if on a temporary
basis), including provision of access to healthcare. Consequently,
a country diagnosing TB in an asylum seeker may elect to
transfer this patient to the country where the application for
asylum was first deposited, even if TB treatment is still ongoing.
More recently, the European Council approved the Directive
2011/24/EU on patients’ rights in cross-border healthcare, as an
attempt to regulate cross-border healthcare in the EU’s free
mobility context by mandating that patients are treated equitably
on the basis of their needs rather than on the basis of their member
state affiliation [22]. It requires that information is provided to the
patients via national contact points for cross-border healthcare,
which need to be set up. National health services will need also
to have access to a repository of information from European
reference networks, where the protection of individual data will
be provisioned by the European Council Directive 95/46/EC [23]
and the Directive 2002/58/EC [24] concerning the processing and
protection of personal data in electronic communications. The
Directive, however, is applicable only to insured EU citizens and
regularly residing third-country nationals, and remains to be fully
implemented.
In March 2011, the European Parliament approved the resolu-
tion on ‘‘Reducing health inequalities in the EU’’ calling on
member states and the EU institutions for universal, equitable
and affordable access to healthcare for all, especially for
undocumented migrants, including access to quality legal
advice and information about their individual rights [25].
In non-EU countries of the WHO European region, related legal
frameworks are rather vague or non-existent [26, 27]. Diverse
national legislations consider cross-border TB control and care.
Some of them ensure free diagnosis and treatment of TB for all
residents irrespective of their nationalities or legal status. Others
are much vaguer and some countries do not have any specific
framework. Those countries, however, are signatories to com-
mitments to uphold the right to health for all [9] and to the
WHO World Health Assembly Resolution 61.17 on ‘‘Health of
migrants’’ [28, 29]. In November 2011, the Committee of
Ministers of the Council of Europe (47 member states) adopted
the recommendations on mobility, migration and the access to
healthcare, further outlining and detailing necessary action at
national level as well as collaboration between states [29].
INTERNATIONAL HEALTH REGULATIONS
Since June 15, 2007, the revised International Health Regulations
(IHR) have been implemented by all countries worldwide [30].
The full implementation of this legally binding agreement will
significantly contribute to global public health security by
providing a framework for the coordinated management of
events that may constitute a public health emergency of
international concern, and by promoting the capacity of all
countries to detect, assess, notify and respond to public health
threats. Although TB is not listed on the group of diseases that
constitute a public health emergency, the network developed for
IHR could be used in promoting the continuum of care of TB
patients. IHR is generally applicable to trans-national TB
transmission; thus, notification of TB to WHO could be con-
sidered if the episode raises an important concern to interna-
tional public health.
Additional details are provided in the online supplementary
material.
EUROPEAN EXPERIENCES ON CROSS-BORDER TB
CONTROL
In spite of the information available on TB cases notified
among migrants in Europe (both in terms of absolute numbers
and proportions) obtained through country surveillance
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(table 1), and on the net migration rate in Europe (difference
between the number of persons entering and leaving a country
during the year per 1,000 persons) (fig. 1) not much is known
about cross-border TB control.
Although several projects aimed at creating a framework of
collaboration on epidemiological issues, in order to improve
communicable disease surveillance, communication and train-
ing across countries, have been implemented in Europe,
academic publications on the topic are scanty and much
remains to be achieved in practice. Examples of such work
include the EpiSouth project [31] for the Mediterranean and the
Balkans and the International Circumpolar Surveillance [32]
and the EpiNorth initiative [33]. Other projects undertook a
situational analysis at the new EU borders and identified needs
for systematic monitoring and provision of adequate health-
care, as well as for cross-sectoral and cross-border collabora-
tion, in view of gaps of continuity of care for asylum seekers
and migrants held in places of detention [34].
At the country level, several recent examples are emerging, as
follows.
In Norway, undocumented migrants in principle have free
access to TB diagnosis. TB suspects may go to the municipal
24-h emergency clinic in the capital, although fear of police
may still create a hindrance. Since 2009, several non-govern-
mental organisations (Church City Mission and Norwegian
Red Cross) have operated a low-profile, low-threshold health
centre for undocumented migrants in the capital city, Oslo.
Once suspected of being affected by TB, the patients can apply
to the migration authorities for temporary permission to stay
in the country. Commonly, this permission is granted, in
accordance with the 2009 revised immigration regulations
stating that foreigners who are under investigation of (or
treatment for) TB should not be forced to leave the country
before the suspicion of disease has been discarded, or the
treatment has been completed [35]. This regulation formalised
the practice established in recent years. Exceptions can be
made in special cases, justifiable from a health perspective, if
there are possibilities for continuum of care, or other special
reasons. Currently, the practice is not to deport TB patients
during treatment, including to the so-called ‘‘Dublin coun-
tries’’. There are presently no indications that this policy has
attracted patients to Norway.
Switzerland has implemented a system of TB screening among
asylum seekers and refugees at the border. The system detects
some cases of TB every year [36]. A larger group of migrants
affected by TB are detected during their stay in the country,
while waiting for a legal decision or after a decision has been
taken. If a case of TB is detected during this period, asylum
seekers are allowed to stay in Switzerland until the completion
of TB treatment, whatever the final decision will be (refugee
status granted or rejected). However, a migrant belonging to the
Dublin Declaration has to leave Switzerland and turn back to the
European country where the application for asylum was first
deposited. If the delay for transfer back allows, the treatment
may be completed in Switzerland. If the delay for transfer back
is too short (i.e. diagnosis of TB shortly before the deadline for
transfer back), the treatment may have to be completed in
another European country. The migration authorities (Swiss
Office for Migrations) offer help and assistance for organising
further treatment at an appropriate service in the country of
transfer. In contrast to asylum seekers and refugees, undocu-
mented migrants with TB are not allowed to stay in the country
and are threatened with rejection and deportation at any time.
Furthermore, they usually have no health insurance which
can cover the costs for TB treatment, except in some cities.
In practice, it is rather easy to postpone rejection, even for
undocumented migrants, until the treatment of TB is completed,
while the financial burden of the TB treatment is the main
problem and has to rely on private or charitable funding.
The Russian Federation is a destination country for thousands
of new migrants from many countries of the former Soviet
Union, including undocumented labour migrants and refugees.
By law and linked to the work and residence permit, they have
to be screened for infectious diseases, including TB, at their own
expense. TB is a condition which can justify deportation within
15 days of diagnosis. In March 2009, a survey was conducted
jointly by the International Organization for Migration (IOM)
and WHO among labour migrants in Tajikistan to elucidate key
factors influencing access to TB diagnosis and treatment both in
their labour destination country (largely the Russian Federation)
and at home. The study showed that migrants have increased
vulnerability to TB due to the working and living conditions in
the destination country and that access to health services is
limited due to their legal status or the high cost of health services
abroad [37]. The preliminary results of the survey were
presented in a round table in Moscow in July 2009 and possible
interventions were identified jointly by the Tajikistan and
Russian participants.
The Netherlands changed the Migration Act at the end of 2009
[38]. Since then has not been allowed by law to deport migrants
to another country while it is suspected that they are affected
by TB. This includes also asylum seekers belonging to the
Dublin Regulation. In the Migration Act it is also laid down
that when migrants (including undocumented migrants,
asylum seekers and foreigners with a temporary permit) are
diagnosed with TB, they have the right to stay legally in the
Netherlands for the whole treatment duration. Unfortunately,
the Migration Act does not allow asylum seekers belonging to
the Dublin Regulation to stay in the country till the completion
of treatment (unless they are still sputum smear positive).
However, relevant efforts have been taken to ensure continua-
tion of their treatment in the country of destination. But this is
often very hard to do and no good follow-up is possible. In
2008, five cases on TB treatment were reported to have been
transferred outside the Netherlands, but it was not clear
whether these transfers were due to the Dublin Regulation and
research had to be started to retrieve more information about
this patient group.
Further to its broader work in continued advocacy for
upholding the right to health for migrants, regardless of status,
and for migrant sensitive health systems, the IOM is perform-
ing health assessment among migrants, as well as for refugees
within the framework of their resettlement to UK, France,
Germany, Norway, Sweden, Finland and several other
European countries. The health assessment protocols signifi-
cantly vary by country but most of them do include TB
screening. The major health assessment project in relation to
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the European countries is the UK TB Detection Programme in
eight high-prevalence countries, where IOM assessed around
482,000 UK visa applicants between October 2005 and December
2010. In several locations, IOM offers treatment to visa applicants
diagnosed with TB, as well as, increasingly, health education.
THE MINIMUM PACKAGE FOR CROSS-BORDER TB
CONTROL AND CARE
The minimum package presented here represents the mini-
mum standards agreed upon among the Wolfheze group of
experts and the NTP managers to ensure cross-border TB
control and care (fig. 2). The recommended minimum package
aims to break down the key barriers to diagnosis and treat-
ment, and data exchange for migrants and other cross-border
travellers with TB.
Governance
The countries shall ensure full commitment to cross-border TB
control and care. A legal framework for TB cross-border
collaboration has to be created in non-EU and EU countries, as
well as between EU countries and non-EU countries of the
WHO European region, to ensure the right to health and the
continuum of TB care for all patients regardless of their legal or
residential status. Continuity of care can be improved by
implementing a few simple activities as follows.
1) The current list of TB services within each member state of
the WHO European region, mentioning one or more ‘‘reference
centre(s)’’ per country specifically identified for this task. The
treating physician will have a useful instrument to refer their
patients in case of need. This list should be ideally kept online
(with restricted access) and regularly updated. The responsi-
bility of updating the e-mail addresses in the list would lie
with each country.
2) The list of national or sub-national focal persons (updated
under care of the WHO Regional Office for Europe), if provided
to physicians in a timely manner, will further facilitate coordina-
tion and hopefully ensure continuity of care. Consensus was
reached to indicate in three working days the maximum time
necessary to share information on the patient moving from a
country to another.
Finance
In the interest of patients’ and public health, health authorities
and providers should have ensured/at their disposal, through
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Ensure funding from government resources, health insurance
and/or bilateral and multilateral funding mechanisms








Early diagnosis including drug-resistant TB
Treatment
Individual patient data
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Relevant indicators at country and regional level 
measure progress
Counselling
Psychosocial support to patients
Empower communities for providing migrant-sensitive services 
Improve communication with migrant communities
Advocate for full engagement of health authorities 
and stakeholders
Feedback to the centre sending patients
Continuity of care
No deportation before the end of treatment or at least until the end 
of intensive phase and ensuring continuation phase treatment 
will be followed
FIGURE 2. The minimum package for cross-border tuberculosis (TB) control and care. EU: European Union; LTBI: latent TB infection.
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enough resources to provide diagnosis and treatment of any
patient, irrespective of their nationality and legal status, in
their country or if moved across the border. Special funds and
treaties need to be established within EU or WHO European
region member states to ensure reciprocity and cover the costs
incurred for treating patients coming from other countries.
A possible common regional fund (regional health insurance)
dedicated to the diagnosis and treatment of patients is strongly
suggested, especially for undocumented migrants, seasonal
workers and international students.
Service delivery
All services should be culturally competent, respectful of
patients’ rights and not be at the cost of the patient [10, 13–15,
39]. These services shall be provided without any interruption
and designed via participatory consultative approaches, invol-
ving patient organisations, cross-border and migrant commu-
nities and associations, as well as those representing staff and
professionals who are directly involved.
1) Prevention: all people who are crossing a border should
have the possibility of accessing preventive measures, includ-
ing diagnosis and treatment of latent TB infection as applic-
able, in the transit, host and return country [13–15, 40].
2) TB infection control: administrative and environmental
measures and respiratory protection shall be provided in
diagnostic and treatment centres as well as during the process
of transferring patients to another country [13–15, 41, 42].
3) Contact management: all relevant family members and
contacts need to be examined for TB and provided treatment if
necessary [43].
4) Diagnosis: all people crossing a border for any reason
should be provided free of charge diagnosis of TB infection and
disease [12, 19] and drug-resistant TB. The diagnosis services
shall be provided in the previously identified ‘‘reference
centres’’. The location of these services shall be decided based
on each country’s health system. Early diagnosis is crucial to
improve treatment outcome and break the transmission in the
community.
5) Treatment: treatment of TB shall promptly be provided by
the first point of contact, irrespective of patients’ legal status.
Treatment of drug resistant TB and TB/HIV co-infection need
to be ensured [44]. Undocumented migrants should not be
deported while on treatment [12, 19]. If they are deported
anyway, at least all pulmonary TB patients subject/subjected to
holding/detention shall receive treatment until they are smear
or culture negative and only after that may an individual be
deemed fit for travel.
6) Continuity of care: patients who are diagnosed with TB shall
be provided quality treatment [13–15] within the country and
beyond the borders. The availability of necessary anti-TB drugs
for continuation of treatment should be verified and ensured
before the patient is transferred to another country [45]. Most
effective for continuity of TB care of undocumented migrants is
not deporting them while on treatment. The continuation of
treatment shall be ensured between the health services of the
country sending and the one receiving the patient.
7) Confidentiality: all health workers are ethically bound and
shall respect, and be protected in doing so, their oath in
maintaining confidentiality and not reporting TB patients,
including undocumented migrants to regulatory authorities
for possible deportation. The exception is the patient who
rejects treatment and poses danger to public health, and then
only after appropriate counselling and psychosocial care; if the
patient still refuses to receive treatment, he/she may be
reported to the regulatory authorities for involuntary medical
isolation. Practising involuntary isolation of patients shall be
only exercised in rare cases and if all other attempts to treat the
patient fail.
Surveillance and monitoring
Before the patient is transferred to another country, the complete
medical records shall be entrusted to the patient and also shared
with the healthcare provider in the recipient country; receipt of
information and feedback need to be sent back to the healthcare
provider sending the patient. The information should be
transmitted in a manner strictly respecting confidentiality and
data protection.
Examples of core indicators for monitoring the cross-border TB
control and care to be adopted with consistency in all countries
include: number of TB patients who were diagnosed as having
TB before or after moving to another country, and number of
TB patients who crossed the border and successfully com-
pleted their treatment.
Supportive environment
Counselling and advice on treatment adherence shall be an
indispensable part of the minimum package for cross-border TB
control and care. Psychosocial support and provision of enablers
and incentives can play a crucial role for promoting treatment
adherence and should be considered a priority intervention.
There is a need to engage civil society organisations, particu-
larly those who can work across the borders and secure
treatment of the patients.
Advocacy, communication and social mobilisation should be
pursued at national and international levels, and in line with
recommendations for provision of migrant sensitive services,
to make this information known to both health providers and
migrant communities and their leaders.
The progress and performance of mechanisms of collaboration
between countries need to be carefully monitored.
CONCLUSIONS
Intensified actions are needed to address the current gaps in
providing TB and drug-resistant TB control and care across
borders. A legal framework for TB cross-border collaboration
has to be created within the EU, in non-EU countries and
between EU and non-EU countries of the WHO European
region, in order to ensure the right to health and the continuum
of TB care for all patients regardless of their legal or residential
status.
In EU countries, an amendment to the Dublin II Regulation on
asylum applications is recommended, in order to foster and
safeguard the continuity of TB care for asylum seekers.
Continuum of TB care between countries should be done
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through a shared updated list of TB services and national
focal points for effective and timely communication regarding
transferred TB patients.
A minimum package for cross-border TB control and care has
been developed by a Wolfheze task force, including known
experts and the NTP managers of the WHO European region.
National health authorities are called to adopt it. For its
successful implementation, a supportive environment is needed
and represented by effective patient support and cross-border
health insurance schemes and funds, engagement of civil society
organisations, advocacy, communication and social mobilisa-
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